In general, a decreased expression of FADD was noted in conditions such as acute myeloid leukemia, thymic lymphoma, glioblastoma, pancreatic cancer, colorectal cancer, renal cancer, and prostate cancer. This evidence concerns the gene FADD and prostate carcinoma.